Compare IH & PLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IH | PLRX |
|---|---|---|
| Founded | 1996 | 2015 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 70.5M | 65.6M |
| IPO Year | 2020 | 2020 |
| Metric | IH | PLRX |
|---|---|---|
| Price | $1.32 | $1.08 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $2.67 |
| AVG Volume (30 Days) | 2.9K | ★ 408.1K |
| Earning Date | 03-31-2026 | 05-06-2026 |
| Dividend Yield | ★ 5.88% | N/A |
| EPS Growth | N/A | ★ 29.97 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $7.30 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.28 | $1.02 |
| 52 Week High | $3.16 | $1.95 |
| Indicator | IH | PLRX |
|---|---|---|
| Relative Strength Index (RSI) | 43.54 | 47.32 |
| Support Level | $1.28 | N/A |
| Resistance Level | $1.45 | $1.27 |
| Average True Range (ATR) | 0.03 | 0.03 |
| MACD | 0.00 | 0.00 |
| Stochastic Oscillator | 22.00 | 55.56 |
iHuman Inc is a Chinese company that uses artificial intelligence to create technology-driven puzzle products for children, making parenting easier and children happier. The company offers a range of intellectual development products that are designed to make the child-rearing experience more manageable for parents while turning intellectual development into a fun journey for children. Its revenue is generated from subscription fees paid by users for premium content on their self-directed and interactive online applications, as well as offline products and other sources. All of the groups revenue is generated from Chinese Mainland.
Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of integrin-based therapies. The company operates as a single reportable segment focused on developing and commercializing novel integrin-based treatments. Its lead product candidate, PLN-101095, is an oral small molecule targeting integrins for the treatment of solid tumors. The company also advances a pipeline of integrin-based programs across multiple disease areas through its proprietary drug discovery platform.